MedTrace Logo

Sodium (23Na) MRI for Tumour Characterisation and Assessment of Therapy Response in Breast Cancer

NCT03940092 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2022-02-28

No results posted yet for this study

Summary

The scope of this study is the methodological development and optimisation of sodium MRI (23Na-MRI) protocols for breast cancer imaging. The study further proposes to utilise biomarkers obtained from 23Na-imaging (cell integrity), FDG-PET (metabolism), multi-parametric MRI (perfusion, vascularity, cellularity, morphology) to generate parameter maps specific for physiological processes in breast cancer.

Conditions

Interventions

OTHER

MRI

This is a prospective, non-randomised, exploratory study on healthy female volunteers (\>18 years), and female patients (\>18 years) diagnosed with primary breast cancer. Healthy volunteers will be scheduled for an 23Na-MRI examination. Patients scheduled for primary surgery will undergo an MR examination, involving 23Na-imaging prior to their planned surgery.

OTHER

PET/MRI

Patients undergoing neo-adjuvant chemotherapy will undertake up to two (2) combined PET/MR examinations with FDG and 23Na-MRI

Sponsors & Collaborators

  • Cambridge University Hospitals NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Fiona Gilbert, FRCR · University of Cambridge

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-13
Primary Completion
2023-12-31
Completion
2025-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03940092 on ClinicalTrials.gov